



(11) **EP 2 965 759 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72

(48) Corrigendum issued on:
11.03.2020 Bulletin 2020/11

(45) Date of publication and mention
of the grant of the patent:
30.10.2019 Bulletin 2019/44

(21) Application number: **15179077.1**

(22) Date of filing: **06.02.2013**

(51) Int Cl.:
A61K 31/415 ^(2006.01) **A61K 31/52** ^(2006.01)
A61K 45/06 ^(2006.01) **A61P 29/00** ^(2006.01)
A61P 1/00 ^(2006.01) **A61P 25/00** ^(2006.01)
A61K 31/5575 ^(2006.01) **A61K 31/196** ^(2006.01)
A61K 31/522 ^(2006.01) **A61K 31/5415** ^(2006.01)
A61K 31/427 ^(2006.01)

(54) **ANTIVIRAL COMPOUND AND COX-2 INHIBITOR COMBINATION THERAPY FOR FIBROMYALGIA**

ANTIVIRALE VERBINDUNG UND COX-2-INHIBITOR-KOMBINATIONSTHERAPIE FÜR
FYBROMYALGIE

COMPOSÉ ANTI-VIRAL ET THÉRAPIE À COMBINAISON D'INHIBITEUR COX-2 POUR LA
FIBROMYALGIE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **06.02.2012 US 201261595507 P**

(43) Date of publication of application:
13.01.2016 Bulletin 2016/02

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
13746016.8 / 2 811 833

(73) Proprietor: **Innovative Med Concepts, LLC**
Tuscaloosa, AL 35406 (US)

(72) Inventor: **Pridgen, William L.**
Tuscaloosa, AL 35406 (US)

(74) Representative: **Haseltine Lake Kempner LLP**
Redcliff Quay
120 Redcliff Street
Bristol BS1 6HU (GB)

(56) References cited:
JP-A- 2008 260 728 US-A- 5 559 114
US-A1- 2002 037 501 US-A1- 2004 030 151
US-A1- 2004 072 144 US-A1- 2004 229 038
US-A1- 2005 119 194 US-A1- 2010 222 289

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).